• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Renovaro Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

    2/19/25 8:45:21 AM ET
    $RENB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RENB alert in real time by email
    false 0001527728 0001527728 2025-02-18 2025-02-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 18, 2025

     

    RENOVARO INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38751   45-2559340
    (State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    2080 Century Park East, Suite 906

    Los Angeles, CA 90067

    (Address of principal executive offices)

     

    +1 (305) 918-1980

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
    Common Stock, par value $0.0001 per share   RENB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

     

    On February 18, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Renovaro Inc. (the “Company”), based on the recommendation of the Company’s management, and after consultation with the Company’s independent registered public accounting firm, concluded that the Company’s previously issued unaudited interim condensed consolidated financial statements contained within the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as amended (the “Q3 2024 Form 10-Q”), (ii) the Company’s previously issued audited consolidated financial statements contained within the Annual Report on Form 10-K for the year ended June 30, 2024 (the “2024 Form 10-K”), and (iii) the Company’s previously issued unaudited interim condensed consolidated financial statements within the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Q1 2025 Form 10-Q” and, together with the Q3 2024 Form 10-Q and the 2024 Form 10-K, the “Prior Filings”) contained material misstatements related to certain warrants which were exercised during the three months ended March 31, 2024, which had not been appropriately reflected as a component of the change in fair value of the contingent consideration in the Prior Filings. Accordingly, those financial statements should no longer be relied upon. Similarly, related reports filed with the Securities Exchange Commission, press releases, shareholder communications, investor presentations or other communications describing relevant portions of the Prior Filings’ financial statements should no longer be relied upon

     

    Accordingly, the Company intends to restate the aforementioned financial statements by amending the Prior Filings as soon as reasonably practicable.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    Certain statements in this Current Report on Form 8-K may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and within the meaning of the federal securities laws. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties such as those set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that are available on the website of the SEC at www.sec.gov and other documents filed, or to be filed with the SEC by the Company. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    RENOVARO INC.  
       
    By: /s/ Nathen Fuentes  
      Name: Nathen Fuentes
    Title: Chief Financial Officer
     

      

    Date: February 19, 2025

     

     

    Get the next $RENB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RENB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RENB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

      LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-performance computing ("HPC") built on the latest platform to accelerate biomarker discovery and next-generation diagnostics. David Weinstein, CEO of Renovaro, stated, "By utilizing Nebul'

      4/22/25 9:20:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Provides Update to Definitive Agreement with Predictive Oncology

      LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025

      4/4/25 9:40:00 AM ET
      $POAI
      $RENB
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RENB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner William Anderson Wittekind disposed of 350,000 shares, decreasing direct ownership by 9% to 3,353,878 units (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      3/12/25 8:12:50 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Van Tilburg Maurice was granted 250,000 shares (SEC Form 4)

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:33:34 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Fuentes Nathen

      4 - RENOVARO INC. (0001527728) (Issuer)

      2/25/25 1:29:46 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $RENB
    SEC Filings

    See more
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      11/6/24 5:45:52 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      10/24/24 8:57:01 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Renovaro Inc.

      SC 13D/A - RENOVARO INC. (0001527728) (Subject)

      6/24/24 7:56:04 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/18/25 5:00:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

      8-K - RENOVARO INC. (0001527728) (Filer)

      4/10/25 4:55:50 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RENOVARO INC. (0001527728) (Filer)

      2/28/25 4:05:41 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RENB
    Leadership Updates

    Live Leadership Updates

    See more
    • Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision neurology company on April 8, 2025. Renovaro's merger with BioSymetrics is designed to enhance Renovaro's data repository and biomarker discovery capabilities, as well as add in vivo vali

      4/9/25 9:25:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

      Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicin

      2/26/25 1:25:00 PM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Renovaro Appoints Nathen Fuentes as Chief Financial Officer

      Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh. Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial l

      1/7/25 9:15:00 AM ET
      $RENB
      Biotechnology: Pharmaceutical Preparations
      Health Care